Pipeline Report: March 2022
March 22nd 2022
Nab-paclitaxel plus pembrolizumab produced an encouraging overall response rate with manageable safety in patients with advanced urothelial cancer who were refractory to platinum-based chemotherapy or cisplatin ineligible, according to data from the phase 2 ABLE trial.
March 19th 2022
Niraparib in combination with bevacizumab was efficacious following 1 line of platinum-based chemotherapy among patients with newly diagnosed advanced ovarian cancer, regardless of biomarker status.